Chairman and Chief Executive Officer
Mr. Mueller currently has dual positions as Chairman and Chief Executive Officer of Immuno Research Inc. He is also a member of the Board of Directors of Biothera Pharmaceuticals Inc. Previously Mr. Mueller was President of Biothera Holding’s ingredient business (Biothera Health Inc.) where he created a global company with immune health ingredient sales in more than 60 countries. He held numerous other executive management and board positions during his career, including: President, Textron Omniquip Alliance Group (NYSE: TXT); President/CEO, Weslock Inc.; Chairman/CEO, Playcore Inc. (AMEX: PCO); and Managing Director/President, Toro-Wheel Horse (NYSE: TTC). He has also held a number of senior management positions with both Toro and 3M Company earlier in his career. He received a bachelor’s degree from the Carlson School of Management, University of Minnesota.
President and Chief Operating Officer
Mr. Karel has extensive senior management experience in the research, development and commercialization of beta glucan and immunotherapy technologies. From 2003-2015, Mr. Karel was Chief Operating Officer responsible for all research and technology development for Immuno Research Inc. (formerly Biothera Inc.) During this period, the company grew its research staff to over 25 scientists, filed over 20 patents, advanced an immunotherapy drug candidate into clinical trials for oncology which was subsequently licensed to Biothera Pharmaceuticals Inc., and worked on the restructuring of the companies businesses, including the sale of its immune health ingredient business and license of technology to Kerry Foods. He is currently a member of the Board of Directors of Biothera Pharmaceuticals Inc. In addition to his role as COO, Mr. Karel served as Chief Financial Officer at Immuno Research Inc. from 1998-2004. He has a bachelor’s degree in Accounting from the University of St. Thomas and began his career as a CPA with KPMG LLP.
Myra Patchen, Ph.D.
Chief Scientific Officer
Dr. Patchen is a leading expert on yeast beta 1,3/1,6 glucans and applications of this Pathogen Associated Molecular Pattern (PAMP) molecule technology. She has spent most of her career researching and developing beta glucans for pharmaceutical applications, primarily oncology and infectious disease, and she has conducted extensive mechanism of action research. Dr. Patchen’s focus on beta glucans spans several companies and senior executive positions, including Chief Scientific Officer of Biothera Inc., Director, Preclinical Pharmacology at Alpha-Beta Technology Inc., and Project Manager at the Armed Forces Radiobiology Research Institute. Dr. Patchen also served as Chief Executive Officer of Sucampo Pharmaceuticals Inc. She received a bachelor’s and a master’s degree in Biology from Bowling Green State University and a Ph.D. in Immunology from the University of Texas. Dr. Patchen has published more than 50 papers on yeast beta glucans.
Mr. Smith has extensive experience in beta glucan technology, most recently serving as President of Biothera Pharmaceuticals Inc. Previously he was the company’s Senior Vice President of Commercial Development. Mr. Smith has more than 30 years of international experience in the pharmaceutical, biotechnology and life sciences sectors in the United States and Europe. Before joining Biothera in 2008, he held senior positions in business development, operations, sales management and research at Amersham International and Sigma Aldrich Corp.